Assay for Sars Coronavirus by Amplification and Detection of the Replicase Sequence

Information

  • Patent Application
  • 20080044816
  • Publication Number
    20080044816
  • Date Filed
    September 13, 2004
    19 years ago
  • Date Published
    February 21, 2008
    16 years ago
Abstract
Primers and probes derived from SARS-CoV nucleic acid that facilitate detection and/or quantification of the replicase gene are disclosed. The disclosed sequences may be used in a variety of amplification and non-amplification formats for detection of SARS-CoV infection.
Description
EXAMPLE 1
DNA Amplification Using SARS-CoV-Specific Primers
Part A:

The ability of the disclosed combination of primers and probes to amplify SARS-CoV nucleic acid was demonstrated using a plasmid DNA clone of the target sequence corresponding to nucleotides 17936-18024 of SARS-CoV strain BJ03 (GenBank Accession No. AY278490). Linearized plasmid DNA was quantified using PicoGreen® dsDNA Quantitation Reagent (Molecular Probes, Inc., Eugene, Oreg.) and diluted to a working concentration with water containing 7 ng/mL salmon sperm DNA. Four replicate SDA reactions were run at each of six target levels, including negative controls that contained water in place of target DNA.


In brief, DNA target was added to SDA Buffer and denatured by heating in a boiling water bath for 5 min. One hundred and ten microliters of the denatured sample was then added to Priming Microwells containing 40 μL of a solution of SDA Primers, Reporter Probe and nucleotides. Following an incubation at ambient temperature for 20 min., the Priming Microwells were transferred to a heat block at 72° C., while corresponding Amplification Microwells containing dried Bst polymerase and BsoBI restriction enzyme were pre-warmed at 54° C. After 10 min. incubation, 100 μL of the priming mixture were transferred from the Priming to the Amplification Microwells, which were then sealed and loaded into a BD ProbeTec ET reader set at 52.5° C. Fluorescent signals were monitored over the course of 1 hour and analyzed using the Passes After Threshold (PAT) algorithm developed for this instrument. (Wolfe D M, Wang S S, Thornton K, Kuhn A M, Nadeau J G, Hellyer T J. Homogeneous strand displacement amplification. In: DNA amplification—current technologies and applications, Demidov V V and Broude N E (Eds.), Horizon Bioscience, Wymondham, UK.) The PAT scores represent the number of instrument passes remaining after the fluorescent readings achieve a pre-defined threshold value. Final SDA reaction conditions were as follows: 50 nM pUC19-based Bumper Primer AB (SEQ ID NO.: 20); 100 nM SDA Primer SarARP (SEQ ID NO.: 3); 500 nM SDA Primer SarAFP (SEQ ID NO.: 2); 250 nM Signal Primer SarAAd-TBD16 (SEQ ID NO.: 4); 500 nM Reporter Probe TBD16 D/R (SEQ ID NO.: 8); 500 μM deoxycytidine 5′-O-(1-Thiotriphosphate), S-isomer (dCsTP); 100 μM each of dATP, dGTP and dTTP; 12.5% DMSO; 25 mM KiPO4; 82 mM KOH; 143 mM bicine; 12 U Bst polymerase; 30 U BsoBI restriction enzyme; 5 mM magnesium acetate.


RESULTS AND CONCLUSIONS

Positive results were obtained with as little 25 copies of the target plasmid per reaction while no false-positive results were observed in any of the negative controls (Table 6). These data demonstrate that the disclosed combination of primers and Reporter Probe is capable of detecting a SARS-CoV-specific nucleic acid target sequence with a high degree of analytical sensitivity.









TABLE 6







Amplification and detection of a SARS-CoV-specific target sequence










Target Level




Per
PAT Score














Reaction
A
B
C
D
Mean


















10000
52
51
49
51
51



1000
52
51
50
51
51



500
50
47
44
50
48



100
50
49
50
49
49



50
37
0
0
43
20



25
35
47
0
47
32



0
0
0
0
0
0







PAT scores: 0 = Negative; >0 = Positive






Part B:

A second experiment was conducted to demonstrate the analytical sensitivity of the disclosed primers for the detection of SARS-CoV-specific nucleic acid. In contrast to the previous experiment, Reporter Probe MPC D/R (SEQ ID NO.: 10) was used together with Signal Primer SarAAd-MPC (SEQ ID NO.: 5).


Briefly, DNA target was added to SDA Buffer and denatured by heating in a boiling water bath for 5 min. One hundred and ten microliters of the denatured sample was then added to Priming Microwells containing 40 μL of a solution of SDA Primers, Reporter Probe and nucleotides. The Priming Microwells were allowed to sit for 20 min. at ambient temperature, before being transferred to a heat block at 72° C. At the same time, corresponding Amplification Microwells containing dried Bst polymerase and BsoBI restriction enzyme were pre-warmed at 54° C. Following a 10 min. incubation, 100 μL of the priming mixture were transferred from the Priming to the Amplification Microwells, which were then sealed and placed at 52.5° C. in a BD ProbeTec ET reader. Fluorescent signals were monitored over the course of 1 hour and analyzed using the PAT algorithm developed for this instrument. The PAT scores represent the number of instrument passes remaining after the fluorescent readings achieve a pre-defined threshold value. Final SDA reaction conditions were as follows: 50 nM pUC19-based Bumper Primer AB (SEQ ID NO.: 20); 100 nM SDA Primer SarARP (SEQ ID NO.: 3); 500 nM SDA Primer SarAFP (SEQ ID NO.: 2); 250 nM Signal Primer SarAAd-MPC (SEQ ID NO.: 5); 500 nM Reporter Probe MPC D/R (SEQ ID NO.: 10); 500 μM dCsTP; 100 μM each of dATP, dGTP and dTTP; 12.5% DMSO; 25 mM KiPO4; 82 mM KOH; 143 mM bicine; 12 U Bst polymerase; 30 U BsoBI restriction enzyme; 5 mM magnesium acetate.


RESULTS AND CONCLUSIONS

Results are summarized in Table 7. All reactions containing 100 copies of plasmid DNA were positive. In contrast, none of the reactions containing water in place of plasmid DNA yielded positive results, thereby demonstrating the analytical sensitivity and specificity of the disclosed of primers and Reporter Probe combination for the detection of the SARS-CoV-specific nucleic acid target sequence.









TABLE 7







Amplification and detection of a SARS-CoV-specific target


sequence using MPC D/R Reporter Probe










PAT Score











100 Targets Per



Replicate
Reaction
Negative Control












A
47.8
0


B
47.9
0


C
47.7
0


D
48.0
0


E
45.9
0


F
46.0
0


G
49.2
0


H
47.6
0


Mean
47.5
0





PAT scores: 0 = Negative; >0 = Positive






EXAMPLE 2
Analytical Specificity

The analytical specificity of the disclosed primers and probes was verified by testing a panel of 43 bacteria and fungi that are likely to be found in respiratory and/or gastrointestinal specimens. Because all these organisms have genomes comprised of DNA rather than RNA, no reverse transcription step was included in these reactions. A suspension of each organism was prepared in Phosphate-Buffered Saline containing Bovine Serum Albumin (PBS/BSA) at a concentration of approximately 107-108 cells/mL. Fifteen microliters of each suspension were mixed with 150 μL SDA Buffer and heated in a boiling water bath for 5 min. to lyse the organisms and denature the DNA. After cooling to room temperature, 110 μL of denatured sample were added to a Priming Microwell containing containing 40 μL of a solution of SDA Primers, Reporter Probe and nucleotides. The Priming Microwells were incubated at ambient temperature for 20 min. and then transferred to a heat block at 72° C., while corresponding Amplification Microwells were pre-warmed at 54° C. After 10 min., 100 μL of the priming mixture were transferred from the Priming to the Amplification Microwells, which were then sealed and loaded into a BD ProbeTec ET reader set at 52.5° C. Fluorescence was monitored over the course of 1 hour and analyzed using the PAT algorithm developed for this instrument. Final SDA conditions were as follows: 50 nM pUC19-based Bumper Primer AB (SEQ ID NO.: 20); 100 nM SDA Primer SarARP (SEQ ID NO.: 3); 500 nM SDA Primer SarAFP (SEQ ID NO.: 2); 250 nM Signal Primer SarAAd-TBD16 (SEQ ID NO.: 4); 500 nM Reporter Probe TBD16 D/R (SEQ ID NO.: 8); 500 μM dCsTP; 100 μM each of dATP, dGTP and dTTP; 12.5% DMSO; 25 mM KiPO4; 82 mM KOH; 143 mM bicine; 12 U Bst polymerase; 30 U BsoBI restriction enzyme; 5 mM magnesium acetate.


RESULTS AND CONCLUSIONS

Results are summarized in Table 8. No positive results were obtained except from a plasmid clone of the SARS-CoV target sequence that was run as a positive control, thereby demonstrating the specificity of the disclosed primers and Reporter Probe for the detection of SARS-CoV.









TABLE 8







Panel of bacteria and fungi tested with the BD ProbeTec


ET SARS-CoV assay












PAT



Species
Strain
Score
Result














Acinetobacter calcoaceticus

BD 13339
0
Negative



Actinomyces israelii

ATCC 10049
0
Negative



Aeromonas hydrophila

ATCC 7966
0
Negative



Alcaligenes faecalis

ATCC 8750
0
Negative



Bacteroides fragilis

ATCC 25285
0
Negative



Bordetella pertussis

ATCC 9797
0
Negative



Candida albicans

ATCC 44808
0
Negative



Chlamydophila pneumoniae

AR-39
0
Negative



Citrobacter freundii

ATCC 8090
0
Negative



Corynebacterium diphtheriae

ATCC 11913
0
Negative



Corynebacterium jeikeium

ATCC 43734
0
Negative



Cryptococcus neoformans

ATCC 36556
0
Negative



Edwardsiella tarda

ATCC 15469
0
Negative



Eikenella corrodens

ATCC 23834
0
Negative



Enterobacter aerogenes

ATCC 13048
0
Negative



Enterococcus faecalis

ATCC 29212
0
Negative



Escherichia coli

ATCC 11775
0
Negative



Fusobacterium nucleatum

ATCC 25586
0
Negative



Haemophilus influenzae

ATCC 33533
0
Negative



Haemophilus parainfluenzae

ATCC 7901
0
Negative



Kingella kingae

ATCC 23330
0
Negative



Klebsiella pneumoniae subsp.

ATCC 13883
0
Negative



pneumoniae




Lactobacillus acidophilus

ATCC 4356
0
Negative



Legionella pneumophila

ATCC 33152
0
Negative



Morganella morganii

ATCC 25830
0
Negative



Neisseria mucosa

ATCC 19696
0
Negative



Peptostreptococcus anaerobius

ATCC 27337
0
Negative



Plesiomonas shigelloides

ATCC 14029
0
Negative



Porphyromonas asaccharolytica

ATCC 25260
0
Negative



Proteus mirabilis

ATCC 29906
0
Negative



Pseudomonas aeruginosa

ATCC 27853
0
Negative



Serratia marcescens

ATCC 8100
0
Negative



Staphylococcus aureus

ATCC 12598
0
Negative



Staphylococcus epidermidis

ATCC E155
0
Negative



Stenotrophomonas maltophila

ATCC 13637
0
Negative



Streptococcus mutans

ATCC 25175
0
Negative



Streptococcus pneumoniae

ATCC 6303
0
Negative



Streptococcus pyogenes

ATCC 19615
0
Negative



Veillonella parvula

ATCC 10790
0
Negative



Yersinia enterolitica

ATCC 27729
0
Negative



Yersinia ruckeri

Not known
0
Negative


SARS-CoV Positive Control
Not
44.7
Positive



Applicable


SARS-CoV Positive Control
Not
41.1
Positive



Applicable


SARS-CoV Positive Control
Not
23.7
Positive



Applicable


SARS-CoV Positive Control
Not
43.3
Positive



Applicable


SARS-CoV Negative Control
Not
0
Negative



Applicable


SARS-CoV Negative Control
Not
0
Negative



Applicable


SARS-CoV Negative Control
Not
0
Negative



Applicable


SARS-CoV Negative Control
Not
0
Negative



Applicable





BD: BD Diagnostics


ATCC: American Type Culture Collection


PAT scores >0 were considered positive






SARS Assay System B Examples
EXAMPLE 1
DNA Amplification Using SARS-CoV-Specific Primers

The ability of the disclosed combination of primers and probes to amplify SARS-CoV nucleic acid was demonstrated using a plasmid DNA clone of the target sequence corresponding to nucleotides 15068-15138 of SARS-CoV strain BJ03 (GenBank Accession No. AY278490). Linearized plasmid DNA was quantified using PicoGreen dsDNA Quantitation Reagent (Molecular Probes, Inc., Eugene, Oreg.) and diluted to a working concentration with water containing 7 ng/μL salmon sperm DNA. Eight replicate SDA reactions were run at each of three target levels, including negative controls that contained water in place of target DNA.


In brief, DNA target was added to SDA Buffer and denatured for by heating in a boiling water bath for 5 min. One hundred and fifty microliters of the denatured sample was then added to Priming Microwells containing dried SDA Primers, Reporter Probe and nucleotides. Following an incubation at ambient temperature for 20 min., the Priming Microwells were transferred to a heat block at 72° C., while corresponding Amplification Microwells containing dried Bst polymerase and BsoBI restriction enzyme were pre-warmed at 54° C. After 10 min., 100 μL of the priming mixture were transferred from the Priming to the Amplification Microwells, which were then sealed and loaded into a BD ProbeTec ET reader set at 52.5° C. Fluorescent signals were monitored over the course of 1 hour and analyzed using the PAT algorithm developed for this instrument. The PAT scores represent the number of instrument passes remaining after the fluorescent readings achieve a pre-defined threshold value. Final SDA reaction conditions were as follows: 50 nM pUC19-based Bumper Primer AB (SEQ ID NO.: 20); 500 nM SDA Primer SarBRP (SEQ ID NO.: 15); 100 nM SDA Primer SarBFP (SEQ ID NO.: 14); 250 nM Signal Primer SarBAd-MPC (SEQ ID NO.: 4); 300 nM Reporter Probe MPC D/R (SEQ ID NO.: 8); 500 mM deoxycytidine 5′-O-(1-Thiotriphosphate), S-isomer (dC8TP); 100 μM each of dATP, dGTP and dTTP; 12.5% DMSO; 25 mM KiPO4; 82 mM KOH; 143 mM bicine; 12 U Bst polymerase; 30 U BsoBI restriction enzyme; 5 mM magnesium acetate.


RESULTS AND CONCLUSIONS

Positive results were obtained with as little 15 copies of the target plasmid per reaction while no false-positive results were observed in any of the negative controls (Table 9). These data demonstrate that the disclosed combination of primers and Reporter Probe is capable of detecting the targeted SARS-CoV-specific nucleic acid sequence with a high degree of analytical sensitivity.









TABLE 9







Amplification and detection of a SARS-CoV-specific target sequence









PAT Score













Negative
15 Targets Per
75 Targets Per



Replicate
Control
Reaction
Reaction







A
0
42
47



B
0
42
47



C
0
46
48



D
0
48
48



E
0
45
48



F
0
46
49



G
0
47
49



H
0
43
45



Mean
0
45
48







PAT scores: 0 = Negative; >0 = Positive






EXAMPLE 2
Analytical Specificity

The analytical specificity of the disclosed primers and probes was verified by testing a panel of 43 bacteria and fungi that are likely to be found in respiratory and/or gastrointestinal specimens. Because all these organisms have genomes comprised of DNA rather than RNA, no reverse transcription step was included in these reactions. A suspension of each organism was prepared in PBS/BSA at a concentration of approximately 107-108 cells/mL. Fifteen microliters of each suspension were mixed with 150 μL SDA Buffer and heated in a boiling water bath for 5 min. to lyse the organisms and denature the DNA. After cooling to room temperature, 110 μL of denatured sample were added to a Priming Microwell containing containing 40 μL of a solution of SDA Primers, Reporter Probe and nucleotides. The Priming Microwells were allowed to sit at ambient temperature for 20 min. and then transferred to a heat block at 72° C., while corresponding Amplification Microwells were pre-warmed at 54° C. After a 10 min. incubation, 100 μL of the priming mixture were transferred from the Priming to the Amplification Microwells, which were then sealed and loaded into a BD ProbeTec ET reader set at 52.5° C. Fluorescence was monitored over the course of 1 hour and analyzed using the PAT algorithm developed for this instrument. Final SDA conditions were as follows: 50 nM pUC19-based Bumper Primer AB (SEQ ID NO.: 20); 500 nM SDA Primer SarBRP (SEQ ID NO.: 15); 100 nM SDA Primer SarBFP (SEQ ID NO.: 14); 250 nM Signal Primer SarBAd-MPC (SEQ ID NO.: 17); 500 nM Reporter Probe MPC D/R (SEQ ID NO.: 10); 500 mM dCsTP; 100 μM each of dATP, dGTP and dTTP; 12.5% DMSO; 25 mM KiPO4; 82 mM KOH; 143 mM bicine; 12 U Bst polymerase; 30 U BsoBI restriction enzyme; 5 mM magnesium acetate.


RESULTS AND CONCLUSIONS

As illustrated in Table 10, no positive results were obtained except from a plasmid clone of the SARS-CoV target sequence that was run as a positive control. This demonstrates the specificity of the disclosed primers and Reporter Probe for the detection of SARS-CoV.









TABLE 10







Panel of bacteria and fungi tested with the BD ProbeTec


ET SARS-CoV assay












PAT



Species
Strain
Score
Result






Acinetobacter calcoaceticus

BD 13339
0
Negative



Actinomyces israelii

ATCC 10049
 0*
Negative



Aeromonas hydrophila

ATCC 7966
0
Negative



Alcaligenes faecalis

ATCC 8750
0
Negative



Bacteroides fragilis

ATCC 25285
0
Negative



Blastomyces dermatitidis

ATCC 4292
0
Negative



Bordetella pertussis

ATCC 9797
0
Negative



Branhamella catarrhalis

ATCC 25238
0
Negative



Candida albicans

ATCC 44808
0
Negative



Chlamydophila pneumoniae

AR-39
0
Negative



Citrobacter freundii

ATCC 8090
0
Negative



Clostridium perfringens

ATCC 13124
0
Negative



Corynebacterium diphtheriae

ATCC 11913
0
Negative



Corynebacterium jeikeium

ATCC 43734
0
Negative



Cryptococcus neoformans

ATCC 36556
0
Negative



Edwardsiella tarda

ATCC 15469
0
Negative



Eikenella corrodens

ATCC 23834
0
Negative



Enterobacter aerogenes

ATCC 13048
0
Negative



Enterococcus faecalis

ATCC 29212
0
Negative



Escherichia coli

ATCC 11775
0
Negative



Fusobacterium nucleatum

ATCC 25586
0
Negative



Haemophilus influenzae

ATCC 33533
0
Negative



Haemophilus parainfluenzae

ATCC 7901
0
Negative



Histoplasma capsulatum

ATCC 12700
0
Negative



Kingella kingae

ATCC 23330
0
Negative



Klebsiella pneumoniae subsp.

ATCC 13883
0
Negative



pneumoniae




Lactobacillus acidophilus

ATCC 4356
0
Negative



Legionella pneumophila

ATCC 33152
0
Negative



Moraxella osloensis

ATCC 19976
0
Negative



Morganella morganii

ATCC 25830
0
Negative



Mycobacterium tuberculosis

ATCC 27294
0
Negative



Mycoplasma pneumoniae

ATCC 29342
0
Negative



Neisseria meningitides

ATCC 13077
0
Negative



Neisseria mucosa

ATCC 19696
0
Negative



Peptostreptococcus anaerobius

ATCC 27337
0
Negative



Plesiomonas shigelloides

ATCC 14029
0
Negative



Porphyromonas asaccharolytica

ATCC 25260
0
Negative



Proteus mirabilis

ATCC 29906
0
Negative



Providencia stuartii

ATCC 35031
0
Negative



Pseudomonas aeruginosa

ATCC 27853
0
Negative



Serratia marcescens

ATCC 8100
0
Negative



Salmonella cholerasuis

ATCC 13076
0
Negative



Staphylococcus aureus

ATCC 12598
0
Negative



Staphylococcus epidermidis

ATCC E155
0
Negative



Stenotrophomonas maltophila

ATCC 13637
0
Negative



Streptococcus mitis

ATCC 6249
0
Negative



Streptococcus mutans

ATCC 25175
0
Negative



Streptococcus pneumoniae

ATCC 6303
0
Negative



Streptococcus pyogenes

ATCC 19615
0
Negative



Veillonella parvula

ATCC 10790
0
Negative



Vibrio parahaemolyticus

ATCC 17802
0
Negative



Yersinia enterolitica

ATCC 27729
0
Negative


SARS-CoV Positive Control
Not
51 
Positive



Applicable


SARS-CoV Positive Control
Not
50 
Positive



Applicable


SARS-CoV Positive Control
Not
51 
Positive



Applicable


SARS-CoV Positive Control
Not
50 
Positive



Applicable


SARS-CoV Negative Control
Not
0
Negative



Applicable


SARS-CoV Negative Control
Not
0
Negative



Applicable


SARS-CoV Negative Control
Not
0
Negative



Applicable


SARS-CoV Negative Control
Not
0
Negative



Applicable





*Negative upon repeat testing; initial result positive (PAT score = 48) due to laboratory contamination


BD: BD Diagnostics


ATCC: American Type Culture Collection


PAT scores >0 were considered positive





Claims
  • 1. A oligonucleotide set comprising a first amplification primer and a second amplification primer, the first amplification primer consisting essentially of SEQ ID NO.: 2 or 14 and the second amplification primer consisting essentially of SEQ ID NO.: 3 or 15.
  • 2. The oligonucleotide set of claim 1 wherein the first amplification primer consists essentially of SEQ ID NO.: 2 and the second amplification primer consists essentially of SEQ ID NO.: 3 or the first amplification primer consists essentially of SEQ ID NO.: 14 and the second amplification primer consists essentially of SEQ ID NO.: 15.
  • 3. (canceled)
  • 4. A oligonucleotide set comprising a first amplification primer and a second amplification primer, the first amplification primer consisting essentially of the target binding sequence of SEQ ID NO.: 2 or 14 and the second amplification primer consisting essentially of the target binding sequence of SEQ ID NO.: 3 or 15.
  • 5. The oligonucleotide set of claim 4 wherein the first amplification primer consists essentially of the target binding sequence of SEQ ID NO.: 2 and the second amplification primer consists essentially of the target binding sequence of SEQ ID NO.: 3 or the first amplification primer consists essentially of the target binding sequence of SEQ ID NO.: 14 and the second amplification primer consists essentially of the target binding sequence of SEQ ID NO.: 15.
  • 6. (canceled)
  • 7. The oligonucleotide set of claim 1, further comprising a signal primer and a reporter probe, the signal primer consisting essentially of the target binding sequence of SEQ ID NO.: 4, 5, 16 or 17 and the reporter probe consisting essentially of SEQ ID NO.: 8 or 10.
  • 8. The oligonucleotide set of claim 7, wherein the signal primer consists essentially of the target binding sequence of SEQ ID NO.: 4 and the reporter probe consists essentially of SEQ ID NO.: 8, the signal primer consists essentially of the target binding sequence of SEQ ID NO.: 5 and the reporter probe consists essentially of SEQ ID NO.: 10, the signal primer consists essentially of the target binding sequence of SEQ ID NO.: 16 and the reporter probe consists essentially of SEQ ID NO.: 8, the signal primer consists essentially of the target binding sequence of SEQ ID NO.: 17 and the reporter probe consists essentially of SEQ ID NO.: 10.
  • 9. (canceled)
  • 10. (canceled)
  • 11. (canceled)
  • 12. The oligonucleotide set of claim 7, further comprising one or more bumper primers consisting essentially of SEQ ID NO.: 1, 12 or 13.
  • 13. The oligonucleotide set of claim 8, wherein the signal primer consists essentially of the target binding sequence of SEQ ID NO.: 5 and the reporter probe consists essentially of SEQ ID NO.: 10 and further comprising a second reporter probe consisting essentially of SEQ ID NO.: 11.
  • 14. The oligonucleotide set of claim 13, further comprising one or more bumper primers consisting essentially of SEQ ID NO.: 1, 12 or 13.
  • 15. The oligonucleotide set of claim 8, wherein the signal primer consists essentially of the target binding sequence of SEQ ID NO.: 17 and the reporter probe consists essentially of SEQ ID NO.: 10 and further comprising a second signal primer and a second reporter probe, the second signal primer consisting essentially of SEQ ID NO.: 17 and the second reporter probe consisting essentially of the hybridization sequence of SEQ ID NO.: 10.
  • 16. The oligonucleotide set of claim 15, further comprising one or more bumper primers consisting essentially of SEQ ID NO.: 1, 12 or 13.
  • 17. The oligonucleotide set of claim 4, wherein the target binding sequences of SEQ ID NOs.: 2, 3, 14 and 15 comprise a sequence required for an amplification reaction.
  • 18. The oligonucleotide set of claim 17, wherein the sequence required for the amplification reaction comprises a restriction endonuclease recognition site that is nickable by a restriction endonuclease or a promoter recognized by an RNA polymerase.
  • 19. (canceled)
  • 20. The oligonucleotide set of claim 7, wherein the hybridization sequences of SEQ ID NOs.: 4, 5, 8, 9, 10, 11, 16 and 17 further comprise an indirectly detectable marker.
  • 21. (canceled)
  • 22. The oligonucleotide set of claim 4, further comprising a signal primer and a reporter probe, the signal primer consisting essentially of the target binding sequence of SEQ ID NO.: 4, 5, 16 or 17 and the reporter probe consisting essentially of SEQ ID NO.: 8, 9, 10 or 11.
  • 23. The oligonucleotide set of claim 22, wherein the signal primer consists essentially of the target binding sequence of SEQ ID NO.: 4 and the reporter probe consists essentially of SEQ ID NO.: 8, the signal primer consists essentially of the target binding sequence of SEQ ID NO.: 5 and the reporter probe consists essentially of SEQ ID NO.: 10, the signal primer consists essentially of the target binding sequence of SEQ ID NO.: 16 and the reporter probe consists essentially of SEQ ID NO.: 8, or the signal primer consists essentially of the target binding sequence of SEQ ID NO.: 17 and the reporter probe consists essentially of SEQ ID NO.: 10.
  • 24. (canceled)
  • 25. (canceled)
  • 26. (canceled)
  • 27. The oligonucleotide set of claim 22, further comprising one or more bumper primers consisting essentially of SEQ ID NO.: 1, 12 or 13.
  • 28. The oligonucleotide set of claim 23, wherein the signal primer consists essentially of the target binding sequence of SEQ ID NO.: 5 and the reporter probe consists essentially of SEQ ID NO.: 10, and further comprising a second reporter probe consisting essentially of SEQ ID NO.: 11.
  • 29. The oligonucleotide set of claim 28, further comprising one or more bumper primers consisting essentially of SEQ ID NO.: 1, 12 or 13.
  • 30. The oligonucleotide set of claim 23, wherein the signal primer consists essentially of the target binding sequence of SEQ ID NO.: 17 and the reporter probe consists essentially of SEQ ID NO.: 10 and further comprising a second signal primer and a second reporter probe, the second signal primer consisting essentially of SEQ ID NO.: 17 and the second reporter probe consisting essentially of the hybridization sequence of SEQ ID NO.: 10.
  • 31. The oligonucleotide set of claim 30, further comprising one or more bumper primers consisting essentially of SEQ ID NO.: 1, 12, 13 or 20.
  • 32. The oligonucleotide set of claim 4, wherein the target binding sequences of SEQ ID NOs.: 2, 3, 14 and 15 comprise a sequence required for an amplification reaction.
  • 33. The oligonucleotide set of claim 32, wherein the sequence required for the amplification reaction comprises a restriction endonuclease recognition site that is nickable by a restriction endonuclease or a promoter recognized by an RNA polymerase.
  • 34. (canceled)
  • 35. The oligonucleotide set of claim 32, wherein the hybridization sequences of SEQ ID NOs.: 4, 5, 8, 9, 10, 11, 16 and 17 further comprise an indirectly detectable marker.
  • 36. (canceled)
  • 37. An oligonucleotide comprising a SARS Coronavirus (SARS-CoV) target sequence consisting essentially of SEQ ID NO.: 6, 7, 18 or 19.
  • 38. A method for detecting the presence or absence SARS-CoV in a sample, the method comprising: (a) treating the sample with a plurality of nucleic acid primers in a nucleic acid amplification reaction wherein a first primer consists essentially of the target binding sequence of SEQ ID NO.: 2 or 14 and a second primer consists essentially of the target binding sequence of SEQ ID NO.: 3 or 15; and(b) detecting any amplified nucleic acid product, wherein detection of the amplified product indicates presence of SARS CoV.
  • 39-45. (canceled)
  • 46. A method for amplifying a target nucleic acid sequence of SARS-CoV comprising: (a) hybridizing to the nucleic acid (i) a first amplification primer consisting essentially of the target binding sequence of SEQ ID NO.: 2 or 14; and(ii) a second amplification primer consisting essentially of the target binding sequence of SEQ ID NO.: 3 or 15; and(b) extending the hybridized first and second amplification primers on the target nucleic acid sequence whereby the target nucleic acid sequence is amplified.
  • 47-57. (canceled)
  • 58. A method of quantifying the amount of SARS-CoV nucleic acid in a target sample comprising the steps of: a) combining the target sample with a known concentration of SARS-CoV internal control nucleic acid;b) amplifying the target nucleic acid and internal control nucleic acid in an amplification reaction;c) detecting the amplified nucleic acid; andd) analyzing the relative amounts of amplified SARS-CoV target nucleic acid and internal control nucleic acid.
  • 59. The method of claim 58, wherein the amplification reaction utilizes one or more signal primers consisting essentially of the hybridization sequence of SEQ ID NO.: 4, 5, 16 or 17 and one or more reporter probes consisting essentially of the hybridization sequence of SEQ ID NO.: 8, 9, 10 or 11.
  • 60. The method of claim 59, wherein the hybridization sequences of SEQ ID NOs.: 4, 5, 8, 9, 10, 11, 16 and 17 comprise an indirectly detectable marker.
  • 61-63. (canceled)
Parent Case Info

The present application claims priority to U.S. Provisional Application Ser. No. 60/502,279, filed Sep. 12, 2003, which is herein incorporated by reference in its entirety.

PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/US04/29691 9/13/2004 WO 00 3/21/2007
Provisional Applications (1)
Number Date Country
60502279 Sep 2003 US